TruSight Tumor 26 takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric and ovarian. This enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation.
TruSight Tumor 26 is a comprehensive assay for examining relevant cancer genes involved in solid tumors, even in challenging FFPE samples.
A multi-institutional study: Evaluation of a novel technique that uses strand-specific information to increase accuracy in a next-generation sequencing assay to identify somatic DNA variants.
A novel approach that improves detection of somatic DNA variants in solid tumors by next-generation sequencing from FFPE samples.
A novel technique that distinguishes low-level somatic DNA variants from FFPE-induced artifacts in solid tumors by next-generation sequencing (NGS).
Note regarding biomarker patents and other patents unique to specific uses of products: Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.